Nemaura Medical (NASDAQ:NMRD) vs. Sintx Technologies (NASDAQ:SINT) Head-To-Head Analysis

Sintx Technologies (NASDAQ:SINT – Get Rating) and Nemaura Medical (NASDAQ:NMRD – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Risk & Volatility

Sintx Technologies has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Sintx Technologies and Nemaura Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sintx Technologies	0	0	1	0	3.00
Nemaura Medical	0	0	2	0	3.00

Sintx Technologies currently has a consensus target price of $136.00, indicating a potential upside of 9,027.52%. Nemaura Medical has a consensus target price of $6.50, indicating a potential upside of 884.85%. Given Sintx Technologies’ higher probable upside, analysts plainly believe Sintx Technologies is more favorable than Nemaura Medical.

Profitability

This table compares Sintx Technologies and Nemaura Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sintx Technologies	-481.33%	-88.02%	-53.84%
Nemaura Medical	N/A	N/A	-75.78%

Institutional and Insider Ownership

3.1% of Sintx Technologies shares are owned by institutional investors. Comparatively, 3.4% of Nemaura Medical shares are owned by institutional investors. 1.0% of Sintx Technologies shares are owned by insiders. Comparatively, 49.8% of Nemaura Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Sintx Technologies and Nemaura Medical’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sintx Technologies	$1.56 million	3.74	-$12.04 million	N/A	N/A
Nemaura Medical	$500,000.00	38.15	-$13.89 million	($0.56)	-1.18

Sintx Technologies has higher revenue and earnings than Nemaura Medical.

Summary

Nemaura Medical beats Sintx Technologies on 6 of the 11 factors compared between the two stocks.

About Sintx Technologies

(Get Rating)

SINTX Technologies, Inc. engages in the development and commercialization of silicon nitride for medical and non-medical applications. It markets spinal fusion products and develops products for use in total hip and knee joint replacements. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in 1996 and is headquartered in Salt Lake City, UT.

About Nemaura Medical

(Get Rating)

Nemaura Medical, Inc. operates as a holding company. The firm engages in the provision of medical device research. It manufactures and commercializes glucose monitoring system, named sugarBEAT. The sugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in New York, NY.